Roche’s Early Alzheimer’s Blood Test Gets FDA Breakthrough Device Designation

Roche has received Breakthrough Device designation from the US Food and Drug Administration (FDA) for its Elecsys pTau217 early Alzheimer’s blood test.

This test, which is being co-developed with Eli Lilly, has the potential to facilitate earlier and more accurate detection of the disease.